Im Cannabis Corp ( (IMCC) ) has released its Q2 earnings. Here is a breakdown of the information Im Cannabis Corp presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IM Cannabis Corp. is an international medical cannabis company that provides premium cannabis products to medical patients in Israel and Germany, leveraging a data-driven approach and a globally sourced product supply chain. In its second quarter of 2025, IM Cannabis reported a strong increase in gross profit and margin growth despite a 14% decline in revenue due to external challenges such as the ongoing conflict in Israel and supply chain delays. Key financial highlights include a 306% increase in gross profit to $3.4 million and a 371% increase in gross margin to 27%. The company also achieved an EBITDA profit of $0.1 million, a significant improvement from a loss of $2.3 million in the same quarter last year. Operating expenses remained stable with a slight increase of 2%. Looking ahead, IM Cannabis management remains optimistic about recovering the revenue impact in the coming quarters and is focused on sustainable, profitable growth as market conditions normalize.